Header Logo

Connection

JOHN KIRKWOOD to Recombinant Proteins

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Recombinant Proteins.
JOHN KIRKWOOD
Connection Strength
3.278
Recombinant Proteins
  1. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
    View in: PubMed
    Score: 0.246
  2. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
    View in: PubMed
    Score: 0.115
  3. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.111
  4. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
    View in: PubMed
    Score: 0.107
  5. Adjuvant Therapy of Melanoma. Cancer Treat Res. 2016; 167:181-208.
    View in: PubMed
    Score: 0.099
  6. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53.
    View in: PubMed
    Score: 0.091
  7. ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.
    View in: PubMed
    Score: 0.085
  8. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol. 2012 Nov 01; 30(31):3773-6.
    View in: PubMed
    Score: 0.079
  9. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
    View in: PubMed
    Score: 0.075
  10. Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011 Sep; 104(4):386-90.
    View in: PubMed
    Score: 0.073
  11. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
    View in: PubMed
    Score: 0.066
  12. Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009 Dec; 1182:47-57.
    View in: PubMed
    Score: 0.065
  13. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009 Jun 01; 27(16):2583-5.
    View in: PubMed
    Score: 0.062
  14. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15; 15(4):1443-51.
    View in: PubMed
    Score: 0.061
  15. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res. 2008 Dec 15; 14(24):8314-20.
    View in: PubMed
    Score: 0.061
  16. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3462-9.
    View in: PubMed
    Score: 0.058
  17. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother. 2008 Sep; 57(9):1315-21.
    View in: PubMed
    Score: 0.058
  18. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
    View in: PubMed
    Score: 0.056
  19. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
    View in: PubMed
    Score: 0.055
  20. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
    View in: PubMed
    Score: 0.054
  21. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
    View in: PubMed
    Score: 0.051
  22. Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b". Oncologist. 2006 May; 11(5):538-9; author reply 539-40.
    View in: PubMed
    Score: 0.051
  23. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.050
  24. Melanoma: therapeutic options with recombinant interferons. Semin Oncol. 1985 Dec; 12(4 Suppl 5):7-12.
    View in: PubMed
    Score: 0.049
  25. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.044
  26. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
    View in: PubMed
    Score: 0.040
  27. Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited. Arch Dermatol. 2003 Jan; 139(1):99; author reply 99-100.
    View in: PubMed
    Score: 0.040
  28. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 01; 20(17):3703-18.
    View in: PubMed
    Score: 0.039
  29. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.039
  30. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
    View in: PubMed
    Score: 0.039
  31. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res. 2002 Aug; 8(8):2480-7.
    View in: PubMed
    Score: 0.039
  32. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002 Apr 15; 20(8):2053-7.
    View in: PubMed
    Score: 0.038
  33. Interferon alfa-2a for melanoma metastases. Lancet. 2002 Mar 16; 359(9310):978-9.
    View in: PubMed
    Score: 0.038
  34. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 01; 62(1):213-8.
    View in: PubMed
    Score: 0.037
  35. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.037
  36. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001 Sep; 137(9):1217-24.
    View in: PubMed
    Score: 0.037
  37. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.
    View in: PubMed
    Score: 0.036
  38. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
    View in: PubMed
    Score: 0.035
  39. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 01; 60(17):4946-52.
    View in: PubMed
    Score: 0.034
  40. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
    View in: PubMed
    Score: 0.034
  41. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-58.
    View in: PubMed
    Score: 0.034
  42. Adjuvant interferon in the treatment of melanoma. Br J Cancer. 2000 May; 82(10):1755-6.
    View in: PubMed
    Score: 0.033
  43. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999 Jan; 5(1):11-20.
    View in: PubMed
    Score: 0.030
  44. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer. 1998 Jul; 34 Suppl 3:S12-7.
    View in: PubMed
    Score: 0.029
  45. Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998 Jun 27; 351(9120):1901-3.
    View in: PubMed
    Score: 0.029
  46. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
    View in: PubMed
    Score: 0.028
  47. Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity. Eur J Cancer. 1997 Aug; 33(9):1345-6.
    View in: PubMed
    Score: 0.028
  48. Interferon adjuvant therapy of melanoma. Cancer. 1997 May 01; 79(9):1843-6.
    View in: PubMed
    Score: 0.027
  49. The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
    View in: PubMed
    Score: 0.027
  50. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol. 1997 Feb; 24(1 Suppl 4):S16-23.
    View in: PubMed
    Score: 0.027
  51. Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
    View in: PubMed
    Score: 0.026
  52. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
    View in: PubMed
    Score: 0.025
  53. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
    View in: PubMed
    Score: 0.024
  54. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol. 1995 Jul; 2(4):365-71.
    View in: PubMed
    Score: 0.024
  55. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8.
    View in: PubMed
    Score: 0.023
  56. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
    View in: PubMed
    Score: 0.019
  57. Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol. 1991 Oct; 86(1):163-72.
    View in: PubMed
    Score: 0.018
  58. Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):83-90.
    View in: PubMed
    Score: 0.018
  59. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011 May 05; 9:52.
    View in: PubMed
    Score: 0.018
  60. Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor. J Immunother (1991). 1991 Apr; 10(2):84-95.
    View in: PubMed
    Score: 0.018
  61. Role of interferons in the therapy of melanoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):180S-184S.
    View in: PubMed
    Score: 0.017
  62. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Oct; 8(10):1637-49.
    View in: PubMed
    Score: 0.017
  63. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15; 116(18):4326-33.
    View in: PubMed
    Score: 0.017
  64. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010 Aug 16; 8:76.
    View in: PubMed
    Score: 0.017
  65. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
    View in: PubMed
    Score: 0.017
  66. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol. 1990 Jun; 8(6):1070-82.
    View in: PubMed
    Score: 0.017
  67. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5748-54.
    View in: PubMed
    Score: 0.015
  68. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 01; 112(5):982-94.
    View in: PubMed
    Score: 0.014
  69. Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
    View in: PubMed
    Score: 0.014
  70. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6796-806.
    View in: PubMed
    Score: 0.014
  71. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007 Sep 01; 25(25):3802-7.
    View in: PubMed
    Score: 0.014
  72. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
    View in: PubMed
    Score: 0.014
  73. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):48-56.
    View in: PubMed
    Score: 0.013
  74. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
    View in: PubMed
    Score: 0.012
  75. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment. Mol Imaging. 2003 Jan; 2(1):65-73.
    View in: PubMed
    Score: 0.010
  76. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002 Mar 01; 20(5):1311-8.
    View in: PubMed
    Score: 0.009
  77. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
    View in: PubMed
    Score: 0.009
  78. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res. 2000 Aug; 9(3):352-63.
    View in: PubMed
    Score: 0.008
  79. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998 May; 16(5):1743-51.
    View in: PubMed
    Score: 0.007
  80. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997 Nov; 15(11):3399-407.
    View in: PubMed
    Score: 0.007
  81. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997 Jun; 15(6):2351-8.
    View in: PubMed
    Score: 0.007
  82. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
    View in: PubMed
    Score: 0.007
  83. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
    View in: PubMed
    Score: 0.007
  84. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Oct; 9(10):1806-10.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.